

Review

# The Neoplastic Side of the Abdominal Wall: A Comprehensive Pictorial Essay of Benign and Malignant Neoplasms

Giorgia Porrello <sup>1,2,\*</sup>, Roberto Cannella <sup>1,3</sup>, Eduardo Alvarez-Hornia Pérez <sup>4</sup>, Giuseppe Brancatelli <sup>1</sup>  
and Federica Vernuccio <sup>5,\*</sup>

- <sup>1</sup> Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnosis (Bi.N.D), University of Palermo, Via del Vespro 129, 90127 Palermo, Italy
- <sup>2</sup> Radiology Unit, Department of Diagnostic and Therapeutic Services, IRCCS ISMETT (Mediterranean Institute for Transplantation and Advanced Specialized Therapies), Via Tricomi 5, 90127 Palermo, Italy
- <sup>3</sup> Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Piazza delle Cliniche, 2, 90127 Palermo, Italy
- <sup>4</sup> Clinica IMQ Zorrotzaurre, 48014 Bilbao, Spain
- <sup>5</sup> Institute of Radiology, Department of Medicine-DIMED, University of Padova, 35128 Padova, Italy
- \* Correspondence: giorgia.porrello@gmail.com (G.P.); federicavernuccio@gmail.com (F.V.)

**Abstract:** Abdominal wall neoplasms are usually benign and, in the majority of these cases, no further work-up or treatment is indicated. The percentage of malignant abdominal neoplasms, however, is not negligible. Radiologists play a pivotal role in identifying imaging features that should favor malignancy, including larger lesion size, edema, neurovascular involvement, and peripheral or inhomogeneous dynamic enhancement, thus indicating to the clinician the need for further work-up. Histopathology is the reference standard for the characterization of abdominal wall neoplasms. In patients undergoing surgery, radiological assessment is needed to guide the surgeon by providing a comprehensive anatomic guide of the tumor extension. We present a pictorial review of benign and malignant abdominal wall neoplasms that can be encountered on radiological examinations, with a main focus on CT and MRI features that help in narrowing the differential diagnosis.



**Citation:** Porrello, G.; Cannella, R.; Alvarez-Hornia Pérez, E.; Brancatelli, G.; Vernuccio, F. The Neoplastic Side of the Abdominal Wall:

A Comprehensive Pictorial Essay of Benign and Malignant Neoplasms. *Diagnostics* **2023**, *13*, 315. <https://doi.org/10.3390/diagnostics13020315>

Academic Editor: Antonio Barile

Received: 27 November 2022

Revised: 5 January 2023

Accepted: 10 January 2023

Published: 15 January 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Keywords:** abdominal wall; incidentaloma; neoplasm; sarcoma; lymphoma; computed tomography; magnetic resonance imaging

## 1. Introduction

Abdominal wall neoplasms may be encountered incidentally on imaging or may present as palpable masses, leading the patient to the radiologist. Malignancies could be identified in about 40% of cases, based on a study by Bashir et al. [1]. However, this percentage is likely overestimated, as this study was based on a population of 365 patients referred to a sarcoma clinic; therefore, the percentage in the overall population is very likely to be much lower. Hence, in most cases, abdominal wall neoplasms have a benign nature and do not require further work-up or treatment.

Radiologists play a pivotal role in recognizing imaging features that deserve close attention. Imaging features that should favor malignancy in soft-tissue tumors of the abdominal wall include larger lesion size, edema, neurovascular involvement, and peripheral or inhomogeneous dynamic enhancement [2,3].

Ultrasonography (US) is the first-line imaging technique for abdominal wall masses, and it is indicated in patients with palpable masses in the abdominal wall. US plays a main role both for diagnosis and as a guide for interventional procedures and biopsies. In many cases, however, abdominal wall neoplasms are identified incidentally on computed tomography (CT) and magnetic resonance (MR) [1].

CT provides information on tumor extension and involvement of deeper abdominal wall structures, but it is burdened by ionizing radiation exposure. Contrast-enhanced MR

is a second-line imaging technique that allows a better understanding of the composition and nature of a mass [2,3]. Histopathology, however, still remains the reference standard for final diagnosis.

Based on the European Society of Musculoskeletal Radiology (ESSR) guidelines on soft tissue tumors, masses above 5 cm should always undergo biopsy after imaging [3].

Benign neoplasms are mainly derived from mesenchymal tissues, with 70% of them classified in six main diagnostic categories: lipomas, fibrous histiocytoma, nodular fasciitis, hemangioma, fibromatosis, and nerve sheath tumors [4,5].

Malignant lesions usually show a larger volume, heterogeneous structure (mainly on MR), and heterogeneous and early contrast enhancement [5]. Around 80% of all abdominal wall malignant primary tumors fall into seven categories: myxofibrosarcoma, liposarcomas, leiomyosarcomas, malignant nerve sheath tumors, synovial cell sarcoma, fibrosarcoma, and sarcoma not otherwise specified (NOS) [4].

This pictorial review aims to provide an overview of the broad spectrum of all these benign and malignant neoplasms, with tips for the differential diagnosis. For each condition, key imaging aspects will be highlighted, in order to provide a complete visual diagnostic guide for the radiologist.

## 2. Imaging Findings: Benign Neoplasms

Table 1 summarizes the main imaging features of benign neoplasms of the abdominal wall.

**Table 1.** Key imaging features of benign neoplasms of abdominal wall. List of abbreviations: T2-weighted images = T2w; T2-weighted images = T1w; contrast = c; diffusion weighted imaging = DWI; apparent diffusion coefficient map = ADC.

Imaging Findings—Benign Neoplasms			
Lesion	Ultrasounds (US)	Computed Tomography (CT)	Magnetic Resonance (MRI)
Lipoma	<ul style="list-style-type: none"> <li>• Homogeneous and isoechoic or hyperechoic in most cases</li> <li>• Hypoechoic in 20% of cases.</li> <li>• No internal vascular flow</li> </ul>	<ul style="list-style-type: none"> <li>• Strongly hypoattenuating</li> <li>• No contrast enhancement</li> </ul>	<ul style="list-style-type: none"> <li>• T2w: moderately hyperintense in non-fat suppressed images</li> <li>• T1w+c: no contrast enhancement</li> <li>• DWI: no restriction</li> <li>• Dual-Echo: no signal drop on out-of-phase</li> </ul>
Desmoid Tumors	<ul style="list-style-type: none"> <li>• Hypoechoic</li> <li>• Poorly circumscribed</li> <li>• Internal vascular flow</li> </ul>	<ul style="list-style-type: none"> <li>• Circumscribed or ill-defined margins</li> <li>• Commonly moderate to high, homogenous enhancement. Tendency to fade, no washout</li> <li>• Larger tumors: calcifications, bleeding, or necrosis</li> </ul>	<ul style="list-style-type: none"> <li>• T1w: low-to-intermediate signal. High if bleeding occurred.</li> <li>• +c: commonly enhancing</li> <li>• T2w: low signal, with high signal foci</li> <li>• DWI: no significant restriction</li> <li>• ADC map: higher values than malignancies</li> </ul>
Hemangioma	<ul style="list-style-type: none"> <li>• Iso-to-hypoechoic</li> <li>• Internal vascular flow</li> <li>• Doppler: arterial waveforms</li> </ul>	<ul style="list-style-type: none"> <li>• +/- Phleboliths</li> <li>• No infiltrating characteristics</li> <li>• Early homogeneous enhancement or progressive centripetal enhancement</li> </ul>	<ul style="list-style-type: none"> <li>• T1w: slightly high</li> <li>• T2w: high</li> <li>• “Blooming artifact” (phleboliths)</li> <li>• Fluid-fluid levels (&gt;2/3)</li> <li>• +c: enhancement</li> </ul>
Nerve Sheath Tumors	<ul style="list-style-type: none"> <li>• Usually hypoechoic</li> <li>• No internal vascular flow</li> </ul>	<ul style="list-style-type: none"> <li>• Low to intermediate attenuation</li> <li>• Contrast enhancement, usually homogeneous</li> </ul>	<ul style="list-style-type: none"> <li>• T1w: low</li> <li>• T2w: heterogeneously high</li> <li>• Cystic degeneration in larger tumors</li> <li>• “Target” and “reverse target sign”</li> <li>• “Split fat sign”</li> </ul>

### 2.1. Lipoma

Lipoma is the most frequent benign soft tissue tumor, with a prevalence ranging from 16% to 50% [1,5,6]. Simple lipomas are homogeneous fatty masses with minimal-to-no enhancement (Figure 1) [6–9]. Their imaging appearance will mirror that of fat and appear as homogeneous and isoechoic or hyperechoic on US; strongly hypodense on CT; and with the same MR signal intensity of subcutaneous and intrabdominal fatty tissues. Of note, Dual Echo sequences will not show signal dropout since lipomas contain extracellular fat.



**Figure 1.** Intramuscular lipoma of the left iliopsoas muscle (arrow). On MR, lipomas are easily studied, as they show well-defined margins and homogeneous fat intensity, as seen on axial (a) and coronal (b) T2w sequences and homogeneous loss of signal on T2 fat-saturated sequences (c).


When inflammation, necrosis, or infarction occur, a heterogeneous appearance [9] with calcifications, thin septa (<2 mm), or bands of muscle fibers can be appreciated [7,8]. In these cases, differentiation with liposarcoma cannot be made at imaging, and biopsy or surgical resection is recommended [6], especially in bigger lesions. When solid components are present, liposarcoma should always be ruled out [6,9].

Lipomas are commonly painless, have no malignant potential, and do not require follow-up. However, subcutaneous lipomas could be surgically removed for symptomatic relief, pathologic confirmation, cosmetic reasons, or if there is an increase in size [9,10]. In these cases, pre-operative CT can be performed to depict their extent. Complete surgical excision including the capsule is advocated to avoid local recurrence. In painful subcutaneous lipomas, either isolated or syndromic (e.g., Dercum’s Disease), management includes options such as liposuction or lidocaine applications [10].

### 2.2. Desmoid Tumors


Desmoid tumors (i.e., “aggressive fibromatosis”) [11] are benign myofibroblast connective tissue tumors, usually occurring in women between 25 and 40 years old [12,13]. Desmoid tumors can be either intra- or extra-abdominal [11], typically do not cross the midline and do not metastasize, but may show infiltrative growth and have a high tendency to recur after resection [7,11,13]. Differential diagnosis includes sarcomas, metastasis, injection granulomas, postsurgical fibrosis, and endometriosis [12].

On imaging, desmoid tumors resemble the surrounding muscles [11–13]. Hypoechoic, poorly circumscribed, with internal vascular flow on US (Figure 2) [7,13], they are commonly briskly hyperattenuating and homogeneous on contrast-enhanced CT, with either circumscribed or ill-defined margins and without washout [13].



**Figure 2.** Desmoid tumors on US. A 45-year-old woman with desmoid tumor of the abdominal wall. B-mode US scan shows a rounded, poorly circumscribed mass in the context of the abdominal muscles (\*), heterogeneously hypoechoic, but similar to muscles that underwent biopsy (right picture).

Larger tumors may appear heterogeneous, as a result of bleeding or necrosis, and may contain calcifications [11–13]. On MR, desmoid tumors have low-to-intermediate T1-weighted (T1-w) signal and high T2-weighted (T2-w) foci, which during subsequent follow-ups become isointense to the surrounding muscles (Figure 3) [3,4,12]. Imaging appearance overlaps with other abdominal wall masses, so tissue sampling is required when desmoids are suspected [1].




**Figure 3.** Desmoid tumor on MR. Axial T2 (a) and T1-weighted (b) contrast-enhanced scan show the typical appearance of a long-standing desmoid tumor (arrow), which is almost indistinguishable from surrounding muscles. After contrast, the mass shows brisk and homogeneous enhancement.

The first sign of a desmoid tumor may be a firm, painless lump. When they develop in flexible, elastic tissues or deep spaces, the tumor can often push normal tissue out of its way as it grows, causing vague symptoms. In the past years, direct complete surgery was the standard primary treatment modality; however, in recent years a paradigm shift towards a conservative management has been introduced in order to prevent local recurrences, as they are usually more aggressive than the original tumor [14]. Moreover, recent studies showed no difference in event-free survival and long-term disease control between patients undergoing surgery and those managed with a conservative approach among patients presenting with favorable locations, such as the abdominal wall [14,15].

### 2.3. Hemangioma

Abdominal wall hemangiomas are rare mesenchymal tumors (<1%), mainly occurring in children [16,17]. US will demonstrate iso- or hypoechoic lesions, similar to surrounding muscles, with ill-defined borders, in the context of abdominal wall muscles [16,18], presenting feeding vessels with arterial parenchymal waveforms on color Doppler, usually with high resistive index (Figure 4) [16–18].



**Figure 4.** Intra-muscular hemangioma in a 2-year-old male patient. US with a linear transducer shows the presence of an echogenic, well-defined mass along the surface of the anterior abdominal wall (arrow, **upper** picture). This lesion shows prominent vascularity, with high-flow arterial waveforms on Doppler integration (**bottom** picture), hallmarks of infantile hemangiomas.

On CT, hemangiomas appear as lesions without clearly infiltrating characteristics, usually with phleboliths, which are punctuate calcifications, suggestive for the diagnosis [8]. In post-contrast sequences, hemangiomas show early homogeneous enhancement or progressive centripetal enhancement [18].


On MR, abdominal wall hemangiomas are isointense or only slightly hyperintense on T1-w images, and hyperintense on T2-w ones [3,8,17], with low-signal spots corresponding to phleboliths, that will create the so-called “blooming artifact” on Dual Echo sequences [16]. Two clues for the diagnosis are the presence of a fat-rim in intramuscular hemangiomas (i.e., an outer loss of signal in all fat-suppressed sequences) [4] and the presence of fluid–fluid levels within the lesion, for more than two thirds of its diameter [4,19], related to slow-moving flows within the hemangioma [19].

Although true hemangiomas have no malignant potential, all management strategies should include regular follow-ups.

Conservative management is the first line of treatment for nearly all isolated intramuscular hemangiomas. When the degree of pain or functional impairment warrants more intervention, nonoperative measures may decrease symptoms, and, if nonresponsive, options include conservative management, topical or systemic corticosteroids, embolization, sclerotherapy, and surgical excision [20].

#### 2.4. Nerve Sheath Tumors

Benign nerve sheath tumors (NSTs) are mainly comprised of neurinomas and schwannomas and are typically located along the course of major peripheral nerves [1,7,8,13]. If multiple lesions are seen, neurofibromatosis type I (NF1) should always be ruled out, [1,3,8,13] as it is associated with a higher risk of malignant degeneration of NSTs and therefore requires periodical follow-up [3]. On US, NSTs appear as smooth well-defined lobulated masses (Figure 5), homogeneously hypoechoic on US, without intralesional vascularization, hypoattenuating on CT, with minimal-to-no enhancement.



**Figure 5.** US appearance of schwannomas. Most schwannomas arise from the nerve sheath of peripheral nerves and occur below or at the level of the subcutaneous fat layer and, as shown, appear as hypoechoic fusiform mass with small blood flow on color Doppler and, sometimes, peripheral nerve continuity.

Neurofibromas and schwannomas contain a solid and a myxoid part and will show low signal on T1-w images, with heterogeneous appearance on T2-w images. A “target sign” could also be appreciated on T2-w sequences [1–4,8], consisting of a peripheral high intensity area, with central low signal, reflecting myxoid degeneration [1,13]. After gadolinium, a “reverse target sign” will appear, given that the enhancement is only central [21]. Another diagnostic tip is the presence of the “split fat sign”, a rim of fat around the tumor [8]. If malignant degeneration occurs, inhomogeneous enhancement and rapid growth will appear, together with ill-defined margins, infiltration, and destructive changes in adjacent bone structures (Figure 6). NSTs of the abdominal wall are usually asymptomatic or just slightly symptomatic and can be managed through follow-up, but are exclusively treated by excision. Prognosis is good with low recurrence rates [22].



**Figure 6.** Malignant schwannoma in a 37-year-old man with neurofibromatosis type 1. Portal venous, axial, contrast-enhanced CT scan demonstrates an infiltrative disease, invading the left iliac bone (arrow), and with heterogeneous contrast enhancement.

**3. Imaging Findings: Malignant Primary Neoplasms**

Table 2 summarizes main imaging features of malignant abdominal wall neoplasms.

**Table 2.** Key imaging features of malignant neoplasms of abdominal wall. List of abbreviations: T2-weighted images = T2w; T2-weighted images = T1w; contrast = c; diffusion weighted imaging = DWI; apparent diffusion coefficient map = ADC; gastrointestinal stromal tumor = GIST; desmoplastic small round cell tumor = DSRCT.

Imaging Findings—Malignant Neoplasms			
Lesion	Ultrasounds (US)	Computed Tomography (CT)	Magnetic Resonance (MRI)
Malignant Schwannoma	<ul style="list-style-type: none"> <li>Heterogeneously hypoechoic</li> </ul>	<ul style="list-style-type: none"> <li>Large/growing masses</li> <li>Irregular margins</li> <li>Heterogeneous enhancement</li> <li>Infiltrating surrounding bones</li> </ul>	<ul style="list-style-type: none"> <li>T1w: heterogeneous</li> <li>T2w: low</li> <li>DWI restriction</li> </ul>
Sarcomas			
Liposarcomas	<ul style="list-style-type: none"> <li>Heterogeneous with lipomatous parts, solid parts, calcifications, cystic degeneration (necrosis)</li> </ul>	<ul style="list-style-type: none"> <li>Sharp demarcation among fatty and nonfatty elements</li> <li>Heterogeneous enhancement</li> <li>+/- calcifications</li> <li>Ill-defined margins, invasion of nearby structures</li> </ul>	<ul style="list-style-type: none"> <li>Low-grade lesions: fat signal with septa/enhancement/small solid foci</li> <li>High-grade lesions: heterogeneous signal depending on the prevalence of each component</li> <li>DWI restriction</li> </ul>
Leiomyosarcomas	<ul style="list-style-type: none"> <li>Heterogeneous</li> </ul>	<ul style="list-style-type: none"> <li>Solid, ill-defined mass with necrotic changes</li> <li>Slight, heterogeneous enhancement</li> </ul>	<ul style="list-style-type: none"> <li>T1w: isointense to muscles</li> <li>T2: high</li> <li>DWI restriction</li> </ul>
GIST	<ul style="list-style-type: none"> <li>Heterogeneous</li> <li>+/- necrosis and cystic degeneration</li> </ul>	<ul style="list-style-type: none"> <li>Soft tissue heterogeneous mass</li> <li>Heterogeneous, enhancement</li> <li>+/- necrosis and cystic degeneration</li> </ul>	<ul style="list-style-type: none"> <li>T1w: low (high if necrosis)</li> <li>T2w: high</li> <li>+/- necrosis and cystic degeneration</li> </ul>


Table 2. Cont.

Imaging Findings—Malignant Neoplasms			
Lesion	Ultrasounds (US)	Computed Tomography (CT)	Magnetic Resonance (MRI)
DSRCT		<ul style="list-style-type: none"> <li>Bulky multiple, hypoattenuating, soft-tissue masses</li> <li>Amorphous calcifications</li> <li>Modest heterogeneous enhancement without washout</li> </ul>	<ul style="list-style-type: none"> <li>T1w: heterogeneously iso-to-hypointense; hyperintense foci if hemorrhage</li> <li>T2w: heterogeneously slightly hyperintense</li> </ul>
Subcutaneous Lymphoma	<ul style="list-style-type: none"> <li>Multiple, well-defined hypoechoic</li> </ul>	<ul style="list-style-type: none"> <li>Confluent masses with homogeneous/heterogeneous slight enhancement, without washout</li> <li>Nodal involvement</li> </ul>	<ul style="list-style-type: none"> <li>T1w: iso-to-hypointense masses</li> <li>T2w: iso-to-hyperintense</li> <li>DWI: restriction</li> </ul>
Metastasis	Mirroring imaging characteristics of primary tumor: usually solid masses with target appearance and rim vascularization, with DWI restriction on MRI.		

### 3.1. Sarcomas

Sarcomas are rare mesenchymal tumors, often large, with poorly defined margins, which can arise in the subcutaneous tissue or in the musculature of the abdominal wall [2,3,23]. The most common types are liposarcomas and leiomyosarcomas [3].

Sarcomas of the abdominal wall are usually non-vascularized solid masses, with necrotic or fluid areas [23], giving the lesion a heterogeneous aspect, mostly hypoechoic on US, with anechoic parts corresponding to fluid degeneration. CT will better characterize extension, staging, and the anatomic origin and will demonstrate hyperattenuating, soft-density structures, with early heterogeneous enhancement (Figure 7) [2,24].



**Figure 7.** US, CT, and MR appearance of sarcomas of the abdominal wall in a 69-year-old male with a palpable mass. B-mode US (first picture) shows the presence of a large, heterogeneously hypoechoic mass, and anechoic areas corresponding to necrosis. Axial, contrast-enhanced CT scan on arterial phase (second picture) shows the presence of a poorly defined mass (arrow) with hazy borders and patchy enhancement. Sagittal, contrast-enhanced MR T1w image (third picture) shows the typical early diffuse enhancement of sarcomas.


Among sarcomas we can distinguish:

- **Liposarcoma:** well-defined fat and myxoid areas will be seen inside a heterogeneously enhancing lesion, with a characteristic sharp demarcation among fatty and nonfatty elements. Calcifications are rare (Figure 8) [3–9,23].



**Figure 8.** Axial, portal venous phase CT shows the appearance of a well-differentiated liposarcoma (arrow) of the left transverse muscle in a 63-year-old woman, presenting as a lobulated mass with fat peripheral attenuation and slight enhancement.


- **Leiomyosarcomas:** seen on the abdominal wall as either a primary process or as an extension of an intra-abdominal process [23,24]. Leiomyosarcomas demonstrate heterogeneous attenuation and signal intensity, with irregular peripheral enhancement and enhancing solid portions, mixed with hemorrhagic and necrotic areas [24]. Fatty components are absent (Figure 9) [23,24].



**Figure 9.** Axial unenhanced CT scan shows a large mass (\*) and a lesion on the subcutaneous fat of the abdominal wall. Histological examination revealed it to be a leiomyosarcoma and had a localization on the abdominal wall (arrow). This entity, when superficial, presents as well-demarcated and homogeneous and, contrary to liposarcomas, does not show fatty component.

- **Gastrointestinal Stromal Tumors (GIST):** either primary (extraintestinal GIST, “EGIST”) [25,26] or secondary GIST of the abdominal wall are rare. When extended (>5 cm), GIST may have an aggressive behavior [25]. CT is the imaging modality of choice, showing heterogeneous vivid enhancement, and variable amount of necrosis. Peculiar findings include calcifications and cystic degeneration [27–29].
- **Desmoplastic Small Round Cell Tumor (DSRCT):** rare, highly aggressive sarcoma of adolescents, which primarily involves the serosal surfaces of the abdominal cavity infiltrating the abdominal wall [30–32]. Classic findings include bulky multiple, hypoattenuating, soft-tissue masses, with omental, serosal, and rectovesical involvement [31,32] and typical punctate or amorphous calcifications [32]. Modest heterogeneous enhancement is seen on arterial phase, without prolonged enhancement or portal


washout [31,32] (Figure 10). On MR, DSRCTs are heterogeneously iso- to-hypointense on T1-w images, with hyperintense foci due to intratumoral hemorrhage [32].



**Figure 10.** A 26-year-old patient coming to medical attention for abdominal tenderness and sudden weight loss. Contrast enhanced sagittal and axial CT scan shows the characteristic CT findings of desmoplastic small round cell tumor (DSRCT): bulky multiple, soft-tissue masses with modest enhancement, and omental, serosal, and rectovesical involvement with rare calcifications, invading the anterior abdominal wall.

### 3.2. Subcutaneous Lymphoma

Lymphoma may involve the subcutaneous tissue, muscles, and skin of the abdominal wall, as a primary process, by contiguous extension or by hematogenous and lymphatic spread [11–13]. The diagnosis is primarily based on diffuse or systemic lymphatic involvement and hepatosplenomegaly [33]. Findings include large masses, nodal or confluent nodal structures, small nodules (<1 cm), disseminated myositis, or panniculitis [13]. On US, subcutaneous lymphoma presents as a well-defined, hypoechoic lesion without increased vascularity [34]. On cross-sectional imaging, confluent masses with homogeneous or heterogeneous enhancement can be appreciated (Figure 11) [13].




**Figure 11.** Axial, contrast-enhanced CT on portal venous phase shows enlarged inguinal (arrows) and retroperitoneal (\*) lymph nodes in a patient with histologically proven non-Hodgkin’s lymphoma.

On MRI, abdominal wall lymphomas show high T2 signal, rarely low-to-intermediate [34], homogenous signal, lack of central necrosis in large lesions [34], lymphangitis, and the “wrapped-around” sign of lymphoma around bony structures [34].

### 3.3. Metastasis


Around 5–10% of all oncologic patients may develop abdominal wall metastases (AWMs) [11]. Secondary AWMs derive from hematogenous or lymphatic spread, direct invasion, or needle-tract seeding [1,13]. When the abdominal wall is the sole potential site of metastasis seen on imaging, biopsy is still recommended (Figure 12) [1].



**Figure 12.** Axial, contrast-enhanced CT (a, arrow) on portal venous phase of a 45-year-old female with history of ovarian cancer treated with laparoscopic surgery demonstrates the presence of a solitary metastatic mass along the right abdominal subcutaneous fat. After laparoscopic surgery, implant tumors can be found along the course of the trocars. Nonetheless, a biopsy was made, as shown on US B-mode picture (b), that confirmed the presence of disease.


Imaging findings are nonspecific [1–3] but include single or multiple soft-tissue nodules that resemble the primary lesion in both appearance and contrast behavior [1]. On CT and MR, heterogeneous or peripheral enhancement will usually be seen [13,35], an appearance called “pseudo-target sign” [4].

Breast cancer is one of the most common causes of abdominal wall and subcutaneous metastasis, with an incidence between 5 and 24% (Figure 13) [36].



**Figure 13.** CT on portal venous phase in a woman who recently underwent quadrantectomy for breast cancer shows multiple nodules spreading from the site of the operation to the subcutaneous fat of the anterior and posterior abdominal wall.


Melanoma metastases are also common, and have a tendency to bleed [11,35–40]. They are hypervascular in 10–17% of cases, with high T1 signal on MR, due to the presence of melanin. Other primary tumors that may lead to AWMs include lung cancer [39], gynecological malignancies, and colorectal cancer (Figure 14) [40,41].



**Figure 14.** A 68-year-old woman with a palpable solid mass on the abdominal wall. Coronal and axial CT scan on portal venous phase showed the presence of a primary lung cancer tumor (A), arrowhead) with multiple implants, including the abdominal wall (arrows, A and B).

AWMs can also be a consequence of laparoscopy, needle biopsies, and radiofrequency ablation [37] in multiple cancers, including hepatobiliary malignancies, neuroendocrine tumors, peritoneal carcinomatosis, and gastric cancer, reaching a prevalence of 16–47% in gynecologic malignancies [35].

A particular AWM appearance is “Sister Mary Joseph’s Nodule” (SMJN), a metastatic deposit located in the umbilicus. SMJN can be the first complaint of an unknown cancer and it is indicative of an aggressive disease [42–46]. The most common primary sites of SMJN are, in order of frequency, pancreato-biliary, gastrointestinal, colorectal, ovarian, and endometrial adenocarcinomas, [35,38,43–46] even though one fourth of cases will derive from undifferentiated cancers (Figure 15) [46]. SMJN can be the first known sign of a malignancy, as the appearance of the navel will alert the patient to seek medical attention.



**Figure 15.** A 50-year-old woman with an umbilical mass. Axial, portal venous phase CT scan shows a collection of masses with heterogeneous, peripheral enhancement metastases along the navel (arrow). It was then demonstrated that the primary site of the tumor was an undifferentiated pancreatic carcinoma.

#### 4. Conclusions

The spectrum of abdominal wall neoplasms is wide, ranging from benign tumors that can be conservatively managed to malignant ones, which require treatment.

The role of the radiologist is fundamental in curtailing the differential diagnosis and correctly interpreting these processes, especially in the case of incidental findings.

Some imaging clues may help to narrow the differential diagnosis, indicating the need for further diagnostic work-up in case of larger lesion size, edema, neurovascular involvement, or peripheral or inhomogeneous dynamic enhancement. Some benign tumors may have atypical features or may lead to complications, and this may lead to diagnostic challenges at imaging and indicate the need for a biopsy to rule out malignancy.

**Author Contributions:** Conceptualization: G.P, R.C., E.A.-H.P., G.B. and F.V.; writing—original draft preparation, G.P.; writing—review and editing, G.P, F.V., R.C., E.A.-H.P., G.B.; supervision, F.V. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** Roberto Cannella: support for attending meetings from Bracco and Bayer; co-funding by the European Union—FESR or FSE, PON Research and Innovation 2014–2020—DM1062/2021. All other authors declare no conflict of interest.

#### References

1. Bashir, U.; Moskovic, E.; Strauss, D.; Hayes, A.; Thway, K.; Pope, R.; Messiou, C. Soft-tissue masses in the abdominal wall. *Clin. Radiol.* **2014**, *69*, e422–e431. [[CrossRef](#)] [[PubMed](#)]
2. Van Rijswijk, C.S.P.; Geirnaerd, M.J.A.; Hogendoorn, P.; Taminiau, A.H.M.; Van Coevorden, F.; Zwinderman, A.H.; Pope, T.L.; Bloem, J.L. Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine-enhanced MR Imaging in Prediction of Malignancy. *Radiology* **2004**, *233*, 493–502. [[CrossRef](#)] [[PubMed](#)]
3. Noebauer-Huhmann, I.M.; Weber, M.-A.; Lalam, R.K.; Trattinig, S.; Bohndorf, K.; Vanhoenacker, F.; Tagliafico, A.; Van Rijswijk, C.; Vilanova, J.C.; Afonso, P.D.; et al. Soft Tissue Tumors in Adults: ESSR-Approved Guidelines for Diagnostic Imaging. *Semin. Musculoskelet. Radiol.* **2015**, *19*, 475–482, correction in *Semin. Musculoskelet. Radiol.* **2015**, *19*, e1. [[CrossRef](#)] [[PubMed](#)]
4. Vanhoenacker, F.M.; Parizel, P.M.; Gielen, J.L. *Imaging of Soft Tissue Tumors*, 3rd ed.; Springer: Berlin, Germany, 2017.
5. Myhre-Jensen, O. A Consecutive 7-Year Series of 1331 Benign Soft Tissue Tumours: Clinicopathologic Data. Comparison with Sarcomas. *Acta Orthop.* **1981**, *52*, 287–293. [[CrossRef](#)] [[PubMed](#)]
6. Toirkens, J.; De Schepper, A.M.; Vanhoenacker, F.; Van Dyck, P.; Gielen, J.; Creytens, D.; Wouters, K.; Eiber, M.; Wörtler, K.; Parizel, P.M. A comparison between histopathology and findings on magnetic resonance imaging of subcutaneous lipomatous soft-tissue tumors. *Insights Imaging* **2011**, *2*, 599–607. [[CrossRef](#)]
7. Ballard, D.H.; Mazaheri, P.; Oppenheimer, D.C.; Lubner, M.G.; Menias, C.O.; Pickhardt, P.J.; Middleton, W.D.; Mellnick, V.M. Imaging of Abdominal Wall Masses, Masslike Lesions, and Diffuse Processes. *Radiographics* **2020**, *40*, 684–706. [[CrossRef](#)]
8. Virmani, V.; Sethi, V.; Fasih, N.; Ryan, J.; Kielar, A. The Abdominal Wall Lumps and Bumps: Cross-Sectional Imaging Spectrum. *Can. Assoc. Radiol. J.* **2014**, *65*, 9–18. [[CrossRef](#)]
9. Gaskin, C.M.; Helms, C.A. Lipomas, Lipoma Variants, and Well-Differentiated Liposarcomas (Atypical Lipomas): Results of MRI Evaluations of 126 Consecutive Fatty Masses. *Am. J. Roentgenol.* **2004**, *182*, 733–739. [[CrossRef](#)]
10. Kucharz, E.J.; Kopeć-Mędrek, M.; Kramza, J.; Chrzanowska, M.; Kotyla, P. Dercum's disease (*Adiposis dolorosa*): A review of clinical presentation and management. *Rheumatology* **2019**, *57*, 281–287. [[CrossRef](#)]
11. Stein, L.; Elsayes, K.M.; Wagner-Bartak, N. Subcutaneous Abdominal Wall Masses: Radiological Reasoning. *Am. J. Roentgenol.* **2012**, *198*, W146–W151. [[CrossRef](#)]
12. Vandevenne, J.E.; De Schepper, A.M.; De Beuckeleer, L.; Van Marck, E.; Aparisi, F.; Bloem, J.L.; Erkorkmaz, Z.; Brijs, S. New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions. *Eur. Radiol.* **1997**, *7*, 1013–1019. [[CrossRef](#)] [[PubMed](#)]
13. Ahn, S.E.; Park, S.J.; Moon, S.K.; Lee, D.H.; Lim, J.W. Sonography of Abdominal Wall Masses and Masslike Lesions: Correlation with Computed Tomography and Magnetic Resonance Imaging. *J. Ultrasound Med.* **2016**, *35*, 189–208. [[CrossRef](#)] [[PubMed](#)]
14. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. *Eur. J. Cancer* **2020**, *127*, 96–107. [[CrossRef](#)]

15. Penel, N.; Le Cesne, A.; Bonvalot, S.; Giraud, A.; Bompas, E.; Rios, M.; Salas, S.; Isambert, N.; Boudou-Rouquette, P.; Honore, C.; et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. *Eur. J. Cancer* **2017**, *83*, 125–131. [[CrossRef](#)] [[PubMed](#)]
16. Shah, P.P.; Dubhashi, S.P.; Choudhary, K. Anterior Abdominal Wall Haemangioma with Inguinal Extension. *J. Clin. Diagn. Res.* **2014**, *8*, ND15–ND16. [[CrossRef](#)] [[PubMed](#)]
17. Saad, D.F.; Shehata, B.M.; Patrick, E.; Gow, K.W. Intramuscular hemangioma of the abdominal wall. *J. Pediatr. Surg.* **2006**, *41*, 601–602. [[CrossRef](#)]
18. Morrow, M.S.; Oliveira, A.M. Imaging of Lumps and Bumps in Pediatric Patients: An Algorithm for Appropriate Imaging and Pictorial Review. *Semin. Ultrasound CT MRI* **2014**, *35*, 415–429. [[CrossRef](#)] [[PubMed](#)]
19. Van Dyck, P.; Vanhoenacker, F.M.; Vogel, J.; Venstermans, C.; Kroon, H.M.; Gielen, J.; Parizel, P.M.; Bloem, J.L.; De Schepper, A.M.A. Prevalence, extension and characteristics of fluid-fluid levels in bone and soft tissue tumors. *Eur. Radiol.* **2006**, *16*, 2644–2651. [[CrossRef](#)]
20. Wierzbicki, J.M.; Henderson, J.H.; Scarborough, M.T.; Bush, C.H.; Reith, J.D.; Clugston, J.R. Intramuscular Hemangiomas. *Sports Health A Multidiscip. Approach* **2012**, *5*, 448–454. [[CrossRef](#)]
21. Vanhoenacker, F.M.; Van Looveren, K.; Trap, K.; Desimpelaere, J.; Wouters, K.; Van Dyck, P.; Parizel, P.M.; De Schepper, A.M. Grading and characterization of soft tissue tumors on magnetic resonance imaging: The value of an expert second opinion report. *Insights Imaging* **2012**, *3*, 131–138. [[CrossRef](#)]
22. Lam, R.; Hunt, B.L.; Arreola-Owen, O. Abdominal Wall Schwannoma. *Fed. Prac.* **2019**, *36*, 129–133.
23. Levy, A.D.; Manning, M.A.; Al-Refaie, W.B.; Miettinen, M.M. Soft-Tissue Sarcomas of the Abdomen and Pelvis: Radiologic-Pathologic Features, Part 1—Common Sarcomas: From the Radiologic Pathology Archives. *Radiographics* **2017**, *37*, 462–483. [[CrossRef](#)] [[PubMed](#)]
24. Eken, H.; Karagul, S.; Topgül, K.; Yoruker, S.; Ozen, N.; Gun, S.; Balci, M.G.; Somuncu, E.; Cimen, O.; Soyuturk, M.; et al. Giant Cutaneous Leiomyosarcoma Originating from the Abdominal Wall: A Case Report. *Am. J. Case Rep.* **2016**, *17*, 35–38. [[CrossRef](#)] [[PubMed](#)]
25. Reith, J.D.; Goldblum, J.R.; Lyles, R.H.; Weiss, S.W. Extragastrointestinal (Soft Tissue) Stromal Tumors: An Analysis of 48 Cases with Emphasis on Histologic Predictors of Outcome. *Mod. Pathol.* **2000**, *13*, 577–585. [[CrossRef](#)]
26. Alkhatib, L.; Albtouch, O.; Bataineh, N.; Gharaibeh, K.; Matalka, I.; Tokuda, Y. Extragastrointestinal Stromal Tumor (EGIST) in the abdominal wall: Case report and literature review. *Int. J. Surg. Case Rep.* **2011**, *2*, 253–255. [[CrossRef](#)]
27. Cannella, R.; Tabone, E.; Porrello, G.; Cappello, G.; Gozzo, C.; Incorvaia, L.; Grignani, G.; Merlini, A.; D'Ambrosio, L.; Badalamenti, G.; et al. Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors. *Eur. Radiol.* **2021**, *31*, 8554–8564. [[CrossRef](#)]
28. Cannella, R.; La Grutta, L.; Midiri, M.; Bartolotta, T.V. New advances in radiomics of gastrointestinal stromal tumors. *World J. Gastroenterol.* **2020**, *26*, 4729–4738. [[CrossRef](#)]
29. Vernuccio, F.; Taibbi, A.; Picone, D.; La Grutta, L.; Midiri, M.; Lagalla, R.; Re, G.L.; Bartolotta, T.V. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response. *Anticancer Res.* **2016**, *36*, 2639–2648.
30. Stiles, Z.E.; Dickson, P.V.; Glazer, E.S.; Murphy, A.J.; Davidoff, A.M.; Behrman, S.W.; Bishop, M.W.; Martin, M.G.; Deneve, J.L. Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma. *J. Surg. Oncol.* **2018**, *117*, 1759–1767. [[CrossRef](#)]
31. Bellah, R.; Suzuki-Bordalo, L.; Brecher, E.; Ginsberg, J.P.; Maris, J.; Pawel, B.R. Desmoplastic Small Round Cell Tumor in the Abdomen and Pelvis: Report of CT Findings in 11 Affected Children and Young Adults. *Am. J. Roentgenol.* **2005**, *184*, 1910–1914. [[CrossRef](#)]
32. Morani, A.C.; Bathala, T.K.; Surabhi, V.R.; Yedururi, S.; Jensen, C.T.; Huh, W.W.; Prasad, S.; Hayes-Jordan, A. Desmoplastic Small Round Cell Tumor: Imaging Pattern of Disease at Presentation. *Am. J. Roentgenol.* **2019**, *212*, W45–W54. [[CrossRef](#)] [[PubMed](#)]
33. Willemze, R.; Cerroni, L.; Kempf, W.; Berti, E.; Facchetti, F.; Swerdlow, S.H.; Jaffe, E.S. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood* **2019**, *133*, 1703–1714. [[CrossRef](#)] [[PubMed](#)]
34. Vanhoenacker, F.M.; Baten, A.; Vandeputte, V. Imaging findings of a cutaneous B-cell lymphoma. *J. Belg. Soc. Radiol.* **2010**, *92*, 285–288.
35. Ataseven, B.; du Bois, A.; Harter, P.; Prader, S.; Grimm, C.; Kurzeder, C.; Schneider, S.; Heikaus, S.; Kahl, A.; Traut, A.; et al. Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. *Int. J. Gynecol. Cancer* **2016**, *26*, 1594–1600. [[CrossRef](#)] [[PubMed](#)]
36. Wichtowski, M.; Murawa, D.; Czarnecki, R.; Piechocki, J.; Nowecki, Z.; Witkiewicz, W. Electrochemotherapy in the Treatment of Breast Cancer Metastasis to the Skin and Subcutaneous Tissue—Multicenter Experience. *Oncol. Res. Treat.* **2018**, *42*, 47–51. [[CrossRef](#)]
37. Heitz, F.; Ognjenovic, D.; Harter, P.; Kommos, S.; Ewald-Riegler, N.; Haberstroh, M.; Gomez, R.; Barinoff, J.; Traut, A.; Du Bois, A. Abdominal Wall Metastases in Patients with Ovarian Cancer After Laparoscopic Surgery: Incidence, risk factors, and complications. *Int. J. Gynecol. Cancer* **2010**, *20*, 41–46. [[CrossRef](#)]
38. Zhong, G.-B.; Ye, X.-Q.; Liu, J.-L.; Xiao, S.-Z.; Huang, Q.-H.; Wei, W. Male accessory breast cancer on the abdominal wall: A case report and literature review. *OncoTargets Ther.* **2018**, *11*, 6625–6631. [[CrossRef](#)]
39. Garrido, M.J.M.; Ponce, C.G.; Martínez, J.L.S.; Sevilla, C.M.Y.; Mena, A.C.; Antón, F.M. Cutaneous metastases of lung cancer. *Clin. Transl. Oncol.* **2006**, *8*, 330–333. [[CrossRef](#)]

40. Attar, L.; Trabulsi, N.; Maghrabi, A.; Nassif, M. Adenocarcinoma of the Colon Disguised as Abdominal Wall Abscess: Case Report and Review of the Literature. *Case Rep. Surg.* **2018**, *2018*. [[CrossRef](#)]
41. Kim, S.W.; Shin, H.C.; Kim, I.Y.; Kim, Y.T.; Kim, C.-J. CT Findings of Colonic Complications Associated with Colon Cancer. *Korean J. Radiol.* **2010**, *11*, 211–221. [[CrossRef](#)]
42. Coll, D.M.; Meyer, J.M.; Mader, M.; Smith, R.C. Imaging appearances of Sister Mary Joseph nodule. *Br. J. Radiol.* **1999**, *72*, 1230–1233. [[CrossRef](#)]
43. Petch, S.; Sobota, A.; Abu Saadeh, F. Sister Mary Joseph nodule: An unusual site for endometrioid cancer metastasis. *BMJ Case Rep.* **2019**, *12*, e229187. [[CrossRef](#)]
44. Ben Kridis, W.; Werda, I.; Khanfir, A. Pancreatic Carcinoma Discovered by Sister Mary Joseph’s Nodules. *Clin. Gastroenterol. Hepatol.* **2018**, *18*, A38. [[CrossRef](#)] [[PubMed](#)]
45. De Angeli, M.; Carosi, M.; Vizza, E.; Corrado, G. Sister Mary Joseph’s nodule in endometrial cancer: A case report and review of the literature. *J. Cancer Res. Ther.* **2019**, *15*, 1408. [[CrossRef](#)] [[PubMed](#)]
46. Bai, X.-L.; Zhang, Q.; Masood, W.; Masood, N.; Tang, Y.; Cao, C.-H.; Fu, Q.-H.; Zhang, Y.; Gao, S.-L.; Liang, T.-B. Sister Mary Joseph’s nodule as a first sign of pancreatic cancer. *World J. Gastroenterol.* **2012**, *18*, 6686–6689. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.